BR112021025645A2 - Degradação de proteína alvo de parp14 para uso em terapia - Google Patents

Degradação de proteína alvo de parp14 para uso em terapia

Info

Publication number
BR112021025645A2
BR112021025645A2 BR112021025645A BR112021025645A BR112021025645A2 BR 112021025645 A2 BR112021025645 A2 BR 112021025645A2 BR 112021025645 A BR112021025645 A BR 112021025645A BR 112021025645 A BR112021025645 A BR 112021025645A BR 112021025645 A2 BR112021025645 A2 BR 112021025645A2
Authority
BR
Brazil
Prior art keywords
parp14
therapy
target protein
protein degradation
quinazolinones
Prior art date
Application number
BR112021025645A
Other languages
English (en)
Inventor
Kalai Swinger Kerren
Wayne Kuntz Kevin
B Schenkel Laurie
Marie Vasbinder Melissa
J N Wigle Timothy
Original Assignee
Ribon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribon Therapeutics Inc filed Critical Ribon Therapeutics Inc
Publication of BR112021025645A2 publication Critical patent/BR112021025645A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

degradação de proteína alvo de parp14 para uso em terapia. a presente invenção refere-se a quinazolinonas e compostos relacionados que degradam parp14 e são úteis, por exemplo, no tratamento de câncer e doenças inflamatórias.
BR112021025645A 2019-06-19 2020-06-18 Degradação de proteína alvo de parp14 para uso em terapia BR112021025645A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962863357P 2019-06-19 2019-06-19
PCT/US2020/038377 WO2020257416A1 (en) 2019-06-19 2020-06-18 Targeted protein degradation of parp14 for use in therapy

Publications (1)

Publication Number Publication Date
BR112021025645A2 true BR112021025645A2 (pt) 2022-02-01

Family

ID=71527971

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021025645A BR112021025645A2 (pt) 2019-06-19 2020-06-18 Degradação de proteína alvo de parp14 para uso em terapia

Country Status (11)

Country Link
US (1) US20220388985A1 (pt)
EP (1) EP3986887A1 (pt)
JP (1) JP2022537349A (pt)
KR (1) KR20220024098A (pt)
CN (1) CN114206853A (pt)
AU (1) AU2020296063A1 (pt)
BR (1) BR112021025645A2 (pt)
CA (1) CA3142002A1 (pt)
MA (1) MA56513A (pt)
SG (1) SG11202112980TA (pt)
WO (1) WO2020257416A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3728207B1 (en) * 2017-12-21 2023-02-01 Ribon Therapeutics Inc. Quinazolinones as parp14 inhibitors
EP4274564A1 (en) * 2021-01-08 2023-11-15 The Board Of Regents Of The University Of Texas System Nimbolide analogs and methods of use thereof
EP4284376A1 (en) * 2021-01-29 2023-12-06 Ribon Therapeutics Inc. Methods of treating inflammatory diseases
CN114890989B (zh) * 2022-05-25 2024-03-22 广东晨康生物科技有限公司 一种含氮衍生物为Linker的HDAC8降解剂其制备方法和应用
US20240101540A1 (en) 2022-07-29 2024-03-28 Ribon Therapeutics, Inc. Targeted protein degradation of parp14 for use in therapy
US20240051946A1 (en) 2022-07-29 2024-02-15 Ribon Therapeutics, Inc. Targeted protein degradation of parp14 for use in therapy
CN117658983A (zh) * 2022-09-01 2024-03-08 浙江文达医药科技有限公司 选择性parp1抑制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR100160A1 (es) * 2014-04-23 2016-09-14 Incyte Corp 1H-PIRROLO[2,3-c]PIRIDIN-7(6H)-ONAS Y PIRAZOLO[3,4-c]PIRIDIN-7(6H)-ONAS COMO INHIBIDORES DE PROTEÍNAS BET
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
EP4310496A2 (en) * 2017-07-12 2024-01-24 Dana-Farber Cancer Institute, Inc. Compounds for tau protein degradation

Also Published As

Publication number Publication date
SG11202112980TA (en) 2021-12-30
AU2020296063A1 (en) 2021-12-23
KR20220024098A (ko) 2022-03-03
JP2022537349A (ja) 2022-08-25
MA56513A (fr) 2022-04-27
CA3142002A1 (en) 2020-12-24
WO2020257416A1 (en) 2020-12-24
EP3986887A1 (en) 2022-04-27
US20220388985A1 (en) 2022-12-08
CN114206853A (zh) 2022-03-18

Similar Documents

Publication Publication Date Title
BR112021025645A2 (pt) Degradação de proteína alvo de parp14 para uso em terapia
BR112018072986A2 (pt) anticorpos anti-pd-1 e anti-lag3 para tratamento de câncer
CR20190350A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
BR112018008326A2 (pt) composições e métodos para o tratamento de câncer
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
EA201890161A1 (ru) Терапевтические композиции, комбинации и способы применения
BR112018011781A2 (pt) molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica
BR112019017403A2 (pt) composições e métodos para o tratamento de câncer
BR112021024236A2 (pt) Proteínas multiespecíficas
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
BR112017023579A2 (pt) combinação de um anticorpo cd30xcd16 com um antagonista de pd-1 para terapia
EA201792348A1 (ru) Биарильные соединения, применяемые при лечении заболеваний человека в онкологии, нефрологии и иммунологии
MX2023002507A (es) Inhibidores de cd73.
BR112015023207A2 (pt) uso de c1-inh no tratamento de desordens associadas à deficiência de inibidor de c1 esterase
BR112022008365A2 (pt) Inibidores de cd73
CL2014001547A1 (es) Compuestos derivados de benzotienilo-pirrolotriazina, como inhibidores de la proteina tirosina quinasa; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o la prevencion de cancer y enfermedades tumorales.
PA8794201A1 (es) Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso
BR112018074232A2 (pt) compostos inibidores de egfr
BR112018016968A2 (pt) derivados de carboxamida úteis como inibidores de rsk
BR112017023517A2 (pt) anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20
BR112017009552A2 (pt) métodos para alvejar o controle transcricional em regiões de super-realçador
BR112022003956A2 (pt) Anticorpos anti-cd73
BR112019024566A2 (pt) inibidores de pirazol magl
EP4273165A3 (en) Interferon beta antibodies and uses thereof
BR112021022784A2 (pt) Composições e métodos para tratamento do câncer